SuperGen to Screen Cancer Drug Targets for GSK

The agreement includes a $3 million investment for compound library screening, as well as royalties and milestones. SuperGen said total payments from GSK could potentially exceed $375 million.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.